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Abstract
Introduction The EORTC QLQ-CR29 is a patient-reported outcome measure to evaluate health-related quality of life among
colorectal cancer patients in research and clinical practice. The aim of this systematic reviewwas to investigate whether the initial
positive results regarding the measurement properties of the QLQ-CR29 are confirmed in subsequent studies.
Methods A systematic search of Embase, Medline, PsycINFO, and Web of Science was conducted to identify studies investi-
gating the measurement properties of the QLQ-CR29 published up to January 2019. For the 11 included studies, data were
extracted, methodological quality was assessed, results were synthesized, and evidence was graded according to the COnsensus-
based Standards for the selection of health Measurement INstruments (COSMIN) methodology on the measurement properties:
structural validity, internal consistency, reliability, measurement error, construct validity (hypothesis testing, including known-
group comparison, convergent and divergent validity), cross-cultural validity, and responsiveness.
Results Internal consistency was rated as “sufficient,” with low evidence. Reliability was rated as “insufficient,” with moderate
evidence. Construct validity (hypothesis testing; known-group comparison, convergent and divergent validity) was rated as
“inconsistent,”with moderate evidence. Structural validity, measurement error, and responsiveness were rated as “indeterminate”
and could therefore not be graded.
Conclusion This review indicates that current evidence supporting the measurement properties of the QLQ-CR29 is limited.
Additionally, better quality research is needed, taking into account the COSMIN methodology.
Highlights • Internal consistency of the QLQ-CR29 is “sufficient”
• Reliability of the QLQ-CR29 is “insufficient”
• Construct validity of the QLQ-CR29 is “inconsistent”
• The other measurement properties were rated as “indeterminate”
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Introduction
Colorectal cancer (CRC) is among the most prevalent cancers
worldwide [1]. CRC and its treatment can have a large impact
on health-related quality of life (HRQOL) [2]. It is important
to assess HRQOL in clinical trials to investigate the impact of
a treatment on HRQOL, and in clinical practice to detect and
monitor symptoms and offer optimal care [3–5]. A frequently
used patient-reported outcome measure (PROM) to evaluate
HRQOL in cancer patients is the 30-item European
Organization for Research and Treatment of Cancer
(EORTC) Quality of Life Core Questionnaire (EORTC
QLQ-C30) [6, 7] and its tumor-specific questionnaire modules
[8]. In 1999, the 38-item module for CRC patients was devel-
oped (EORTC QLQ-CR38) [9], and in 2007, the module was
revised and shortened to 29 items (EORTC QLQ-CR29) [10].
The initial validation study of the QLQ-CR29 in an interna-
tional sample of CRC patients [11] showed that it had good
internal consistency (α > 0.70) in all but one subscale, was
acceptably reliable (intraclass correlation coefficient (ICC) >
0.68 for subscales and > 0.55 for single items), was able to
discriminate between known groups (patients with and with-
out stoma, Karnofsky performance score < 80 and > 80, and
with curative and palliative treatment), and had good diver-
gent validity, i.e., low correlation with QLQ-C30 items [11].
Two systematic reviews on the measurement properties of
the QLQ-CR29 were published in 2015 and 2016 [12, 13].
Wong et al. performed a systematic review on various disease-
specific and generic HRQOL PROMs, and included two stud-
ies on the QLQ-CR29. They recommended the QLQ-CR38 to
assess HRQOL in CRC patients, because it had the most pos-
itive ratings on the measurement properties according to their
quality assessment criteria [12]. Ganesh et al. performed a
systematic review of three CRC-specific PROMs
(Functional Assessment of Cancer Therapy-Colorectal
(FACT-C), QLQ-CR38, and QLQ-CR29), and included three
studies on the QLQ-CR29. They concluded that the choice for
one of these three instruments depends on the context and the
research aim [13].
Since these reviews, several new validation studies of the
QLQ-CR29 have been published. Therefore, the aim of the
present study was to perform a systematic review of the mea-
surement properties of the QLQ-CR29 as investigated in val-
idation studies up to 2019, according to the COnsensus-based
Standards for the selection of health Measurement
INstruments (COSMIN) criteria [14, 15], and to investigate
whether the initial positive results regarding the measurement
properties of the QLQ-CR29 are confirmed.
Materials and methods
EORTC QLQ-CR29
The EORTC QLQ-CR29 is a tumor-specific HRQOL ques-
tionnaire module for CRC patients, which is designed to com-
plement the EORTC QLQ-C30 questionnaire [6, 10]. The
QLQ-CR29 has five functional and 18 symptom scales. It
contains four subscales (urinary frequency (UF), blood and
mucus in stool (BMS), stool frequency (SF), and body image
(BI)) and 19 single items (urinary incontinence, dysuria, ab-
dominal pain, buttock pain, bloating, dry mouth, hair loss,
taste, anxiety, weight, flatulence, fecal incontinence, sore skin,
embarrassment, stoma care problems, sexual interest (men),
impotence, sexual interest (women), and dyspareunia) [11].
Patients are asked to indicate their symptoms during the past
week(s). Scores can be linearly transformed to provide a score
from 0 to 100. Higher scores represent better functioning on
the functional scales and a higher level of symptoms on the
symptom scales [10, 11].
Literature search
The literature search was part of a larger systematic review
(Prospero ID 42017057237) [16], investigating the validity of
39 PROMs measuring HRQOL of cancer patients included in
an eHealth self-management application “Oncokompas”
[17–21]. We performed a systematic search of Embase,
Medline, PsycINFO, and Web of Science, to identify studies
investigating the measurement properties of these 39 PROMs,
including the QLQ-CR29. The search terms were the PROM’s
name, combined with search terms for cancer, and a precise
filter for measurement properties [22]. The full search terms
can be found in Appendix. The literature search was per-
formed in June 2016 and updated in January 2019 to search
for recent studies on the QLQ-CR29 specifically. References
of included studies have been checked for additional articles
manually.
Inclusion and exclusion criteria
Inclusion criteria were as follows: reporting original data from
cancer patients on at least one measurement property of the
QLQ-CR29, as defined in the COSMIN taxonomy [15, 23,
24]—structural validity (the degree to which the scores of a
PROM are an adequate reflection of the dimensionality of the
construct to be measured), internal consistency (the degree of
interrelatedness among items), reliability (the extent to which
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scores of patients who have not changed are the same for
repeated measures on different occasions), measurement error
(the error of a patient’s score that is not attributed to true
changes in the construct to be measured), construct validity
(hypothesis testing; including known-group comparison, con-
vergent and divergent validity [the degree to which the scores
of a PROM are consistent with hypotheses with regard to
differences between relevant groups, and relationships to
scores of other instruments, respectively]), cross-cultural va-
lidity (the degree to which the performance of the items on a
translated or culturally adapted PROM are an adequate reflec-
tion of the performance of the items of the original version of
the PROM), and responsiveness (the ability of a PROM to
detect change over time in the construct to be measured)
[24]. Exclusion criteria were as follows: no availability of
full-text manuscripts, conference proceedings, and non-
English publications. Titles and abstracts, and eligible full
texts were screened by two of the four raters independently
(KN, FJ, AH, NH). Disagreements were discussed until con-
sensus was reached.
Data extraction
For each reported measurement property defined by the
COSMIN taxonomy [25], data were extracted by two of the
four extractors independently (KN, FJ, AH, NH). This includ-
ed type of measurement property, its outcome, and informa-
tion on methodology. Disagreements were discussed until
consensus was reached.
Data synthesis
For the data synthesis, we followed the three steps of the
COSMIN guideline for systematic review of PROMs [26].
In step 1, we rated methodological quality of the studies per
reported measurement property as either “excellent,” “good,”
“fair,” or “poor.” A total score was obtained by taking the
lowest rating on any of the methodological aspects, according
to the original COSMIN checklist [14]. In step 2, we rated the
results per measurement property, by applying the COSMIN
criteria for good measurement properties [26]. Results of the
individual studies were rated as “sufficient,” “insufficient,” or
“indeterminate” per measurement property, according to
predefined criteria. Ratings from the individual studies were
then qualitatively summarized into an overall rating per mea-
surement property. Inconsistencies between studies were ex-
plored. If any explanation was found (e.g., poor methodolog-
ical quality), this was taken into account in the overall rating,
if no explanation was found, the overall rating was summa-
rized as “inconsistent.” In step 3, we graded the quality of the
evidence of the measurement properties, following a modified
GRADE approach [26]. The overall quality of the evidence
was rated as “high,” “moderate,” “low,” or “very low,” taking
into account risk of bias, inconsistency of study results, im-
precision, and indirectness. When a measurement property
was rated as “indeterminate” in step 2, the quality of evidence
could not be graded, as there was no evidence to grade. The
evaluation of measurement properties was performed by two
raters independently (AH, NH). Disagreements were
discussed until consensus was reached.
Results
In the initial search, 980 nonduplicate abstracts were identified
for all 39 PROMs, of which 31 were relevant for the QLQ-
CR29. The search update resulted in 27 extra nonduplicate
abstracts regarding the QLQ-CR29. In total, 55 abstracts were
screened, of which 30 were excluded. Thirteen studies were
excluded during full-text screening. One study was excluded
during data extraction [27], because data were not presented
for the QLQ-CR29 separately. The flow diagram of the liter-
ature search and selection process is shown in Supplementary
Fig. 1. Study characteristics of the 11 included studies [11,
28–37] are shown in Table 1. These studies reported on struc-
tural validity (9 studies), internal consistency (10 studies),
reliability (6 studies), construct validity (know-group compar-
ison [10 studies], convergent [8 studies], and divergent [2
studies] validity), and responsiveness (2 studies), but did not
report on measurement error, or cross-cultural validity.
However, measurement error could be calculated for four
studies.
Structural validity
Nine studies investigated structural validity (Table 2).
Methodological quality of eight studies was rated as “poor”
[11, 28, 30–32, 34–36], because they performed multitrait
item scaling (MIS) instead of exploratory/confirmatory factor
analysis (EFA/CFA). One study was rated as “fair” [37], be-
cause it performed a principal component analysis (PCA). The
studies reporting MIS were consistent in their findings, show-
ing no inconsistent items regarding convergent and discrimi-
nant validity within the subscale. However, since MIS is an
indirect test of structural validity, no conclusions can be drawn
on the basis of these studies. In the study that used PCA, three
of the four original subscales (UF, BMS, and BI) were repli-
cated. The two-item original SF subscale was merged with
four single items about bowel or stoma problems into a new
subscale “defecation/stoma problems (DSP)” [37]. Because
the account of variability and the ratio of the explained vari-
ance by the factors was not reported, the PCA cannot be
interpreted properly, and therefore structural validity was rat-
ed as “indeterminate,” and there is no evidence for or against
unidimensionality of the subscales.
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Table 1 Study characteristics of the included studies
Reference Year of
publication
Research aim Population Sample
size
Language Characteristic of
study sample
Arraras
et al. [28]
2011 Validation of QLQ-CR29 Spanish rectal
cancer
patients
84 Spanish Sex, 67% male
Stoma, 29% yes
Tumor type, 100%
rectal cancer
Age, 65.2 ± 9.5 (44–82)
Hou et al. [29] 2015 Validation of Low Anterior
Resection Syndrome
(LARS) score
Chinese rectal
cancer patients
102 Chinese Sex, 58% male
Stoma, 22% yes
Tumor type, 100%
rectal cancer
Age, 66.5 ± 10.7 (37–86)
Ihn
et al. [30]
2015 Validation of QLQ-CR29 Korean CRC
patients
123 Korean Sex, 69% male
Stoma, not reported
Tumor type, 50% CRC,
50% rectal cancer
Age, 60.1 ± 9.6
Lin et al. [31] 2017 Validation of QLQ-CR29 Chinese CRC
patients
356 Chinese
(Simplified
Chinese)
Sex, 63% male
Stoma, not reported
Tumor type, 56% CRC,
43% rectal cancer, 1%
both
Age, 54.5 ± 13.5
Magaji et al. [32] 2015 Validation of QLQ-CR29 Malaysian CRC
patients
93 Bahasa Malaysian Sex, 59% male
Stoma, 34% yes
Tumor type, 52% CRC,
38% rectal cancer,
10% unknown
Age, not reported
Montazeri et al. [33] 2018 Validation of QLQ-CR29 Iranian CRC
patients
100 Persian Sex, 47% male
Stoma, 33%
Tumor type, not reported
Age, 53.6 ± 12.6 (22–78)
Nowak et al. [34] 2011 Validation of QLQ-CR29
(pilot)
Polish rectal
cancer
patients
20 Polish Sex, 50% male
Stoma, 50% yes
Tumor type, 100% rectal
cancer
Age, not reported
Sanna et al. [35] 2017 Validation of QLQ-CR29 Polish CRC
patients
150 Polish Sex, 61% male
Stoma, 30% yes
Tumor type, 61% CRC,
39% rectal cancer
Age, 68 ± 12.5 (32–85)
Shen et al. [36] 2018 Validation of QLQ-CR29 Taiwanese
CRC
patients
108 Traditional Chinese
(Mandarin)
Sex, 58% male
Stoma, 10%
Tumor type, 64% CRC,
36% rectal cancer
Age, 63.7 ± 13.2 (22–89)
Stiggelbout et al. [37] 2015 Validation of QLQ-CR29 Dutch CRC patients 236 Dutch Sex, 61% male
Stoma, 29% yes
Tumor type, not reported
Age, 65 ± 11.3 (24–90)
Whistance et al. [11] 2009 Validation of QLQ-CR29
(original validation)
International
population of
CRC patients
351 Spanish, English,
French, Taiwanese,
Italian, German
Sex, 58% male
Stoma, 33% yes
Tumor type, 56% CRC,
44% rectal cancer, 1%
unknown
Age, 65.0 ± 11.9
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Internal consistency
Ten studies investigated internal consistency (Supplementary
Table 1). Methodological quality of nine studies was rated as
“poor” [11, 28, 30–36], because evidence for unidimensionality
of the subscales was not provided, and therefore, the value of
Cronbach’s α could not be interpreted properly [38]. One study
was rated as “fair” [37], because it did not report on howmissing
items were handled. This study reported good internal consisten-
cy for the BI subscale (α = 0.80), and the new subscale
established (see “Structural validity”); DSP (α = 0.84). The sub-
scale UF had adequate internal consistency (α = 0.71), and for
the original subscale SF two values were presented; for patients
with (α = 0.72) andwithout stoma (α= 0.68). The subscale BMS
had low internal consistency (α = 0.56) [37]. The studies of poor
quality showed mostly adequate Cronbach’s α values, except for
the BMS subscale. Based on these findings, the evidence on
internal consistency was rated “sufficient,” because > 75% of
the values were good for the original subscales, assuming these
subscales are unidimensional, which is not provenwith PCA (see
“Structural validity”). Quality of evidence was graded as “low,”
because only one study of fair quality was found.
Reliability
Six studies investigated test–retest reliability (Table 3).
Methodological quality of two studies was rated as “poor” [36,
37], because of the small sample size. Four studies were rated as
“fair” [11, 30, 32, 35], because it was not reported how missing
items were handled and/or had a moderate sample size. Two of
these studies [11, 32] provided an overall ICC value for all
subscales/items with exceptions (e.g., “ICC for all subscales
was > 0.66, except for BI”), and thereby provided too little infor-
mation to interpret the ICC on the subscale/item level. Low
Table 2 Structural validity of the EORTC QLQ-CR29
Reference Methodology Results Quality Rating
Arraras et al.
[28]
MIS Most items exceeded correlations of 0.4 with other items in their own subscale,
except for items 38 and 39 (BMS subscale).
All items had a higher correlation with other items in
their own scale than with items in other subscales, except for item 38 (blood in stool).
Poor Indeterminate
Ihn et al. [30] MIS All items exceeded correlations of 0.4 with other items in their own subscale,
for the total population and for patients with and without stoma.
All items had a higher correlation with other items in their own subscale, than with
items in other subscales, for the total population and for patients with and without stoma.
Poor Indeterminate
Lin et al. [31] MIS All items exceeded correlations of 0.4 with other items in their own subscale.
All item had a higher correlation with other items in their own subscale than with
items in other subscales.
Poor Indeterminate
Magaji et al.
[32]
MIS All items exceeded correlations of 0.4 with other items in their own subscale,
for the total population and for patients with and without stoma.
All items had a higher correlation with other items in their own subscale than with
items in other subscales, for the total sample, as well as patients with and without stoma.
Poor Indeterminate
Nowak et al.
[34]
MIS Most items exceeded correlations of 0.4 with other items in their own subscale, for the total
population. For the BMS subscale, convergent and divergent validity could not
be estimated for the total population. In subgroups of patients with and without
stoma, mixed results with also negative correlations were shown.
Most items had a higher correlation with items in other subscales, than with items
in their own subscale, for the total population and for patients with and without stoma.
Poor Indeterminate
Sanna et al.
[35]
MIS All items exceeded correlations of 0.4 with other items in their own subscale
for the total population and for patients with and without stoma.
All items had a higher correlation with other items in their own subscale than with
items in other subscales, for the total population and for patients with and without stoma.
Poor Indeterminate
Shen et al.
[36]
MIS All items exceeded correlations of 0.4 with other items in their own subscale.
All items had higher correlations with other items in their own subscale than with
items in other subscales.
Poor Indeterminate
Stiggelbout
et al. [37]
PCA Seven factors were revealed, of which three of the original subscales were reproduced. The
two-item original factor SF was combined with all items about bowel and stoma
problems into a new six-item subscale, Defaecation/Stoma Problems (DSP).
All remaining factors did not form clearly interpretable subscales.
Fair Indeterminate
Whistance
et al. [11]
MIS All items exceeded correlations of 0.4 with other items in their own subscale, for the total
sample, as well as for patients with and without stoma, except for the BMS subscale in
patients with a stoma (0.37).
All items had a higher correlation with other items in their own subscale than with
items in other subscales, for the total sample, as well as patients with and without stoma.
Poor Indeterminate
MIS multitrait item scaling analysis, PCA principal component analysis
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Table 4 Known group comparison of the QLQ-CR29
Reference Comparison groups Outcome a Quality Rating
Arraras et al. [28] Fair Insufficient
Age (45–65 vs. 66–82 years) Older patients (66–82 years) had significantly
lower functioning scores related to sexual
interest (men), higher symptom scores
related to taste, and lower symptom scores
related to dyspareunia (women), compared
to younger patients (45–65 years).
Limiting comorbidity (yes vs. no) Patients with limiting comorbidity had
significantly lower functioning scores related
to sexual interest (men), and higher
symptom scores related to impotence (men),
compared to patients without limiting
comorbidity.
Performance status
(Karnofsky score ≤ 90 vs. > 90)
Patients with a lower performance status
(KPS ≤ 90) had significantly higher symptom
scores related to blood and mucus in
stool, compared to patients with a higher
performance status (KPS > 90).
Adjuvant chemotherapy (yes vs. no) Patients who received chemotherapy had
significantly lower symptom scores related to
taste, compared to patients who did not
receive chemotherapy.
Type of surgery and presence
of stoma (low anterior resection
vs. abdominoperineal resection)
Patients with low anterior resection surgery had
significantly higher symptom scores related to
stool frequency, compared to patients with
abdominoperineal resection surgery.
Ihn et al. [30] Poor Indeterminate
Cancer type (rectal cancer
vs. colon cancer)
Patients with rectal cancer had significantly lower
functioning scores related to body image, anxiety
and weight, and higher symptom scores related
to urinary incontinence, abdominal pain, buttock
pain, hair loss, taste, flatulence, fecal incontinence,
sore skin, embarrassment and impotence (men),
compared to patients with colon cancer.
Neoadjuvant therapy
(yes vs. no)
Rectal cancer patients who had neoadjuvant therapy
had significantly lower functioning scores related
to body image and anxiety, compared to rectal
cancer patients who did not have neoadjuvant
therapy.
Stoma (yes vs. no) Rectal cancer patients with a stoma had significantly
lower functioning scores related to body image,
anxiety and weight, and higher symptom scores
related to sore skin and embarrassment, compared
to rectal cancer patients without stoma.
Lin et al. [31] Poor Indeterminate
Stoma (yes vs. no) Patients with a stoma had significant lower
functioning scores related to body image, anxiety,
and weight, and higher symptom scores related to
urinary incontinence, buttock pain, dry mouth,
flatulence, fecal incontinence, sore skin and
embarrassment, and lower symptom scores related
to taste, compared with patients without a stoma.
Performance status
(Karnofsky score
≤ 80 vs. > 80)
Patients with a lower performance status (KPS ≤ 80)
had significant higher functioning scores related
to anxiety, weight, sexual interest (men) and sexual
interest (women), lower symptom scores related to
urinary frequency, dysuria, buttock pain, hair loss,
flatulence, fecal incontinence, sore skin,
embarrassment, impotence (men) and dyspareunia
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Table 4 (continued)
Reference Comparison groups Outcome a Quality Rating
(women), and higher symptom scores related to
blood and mucus in stool, stool frequency, bloating
and taste, compared with patients with a higher
performance status (KPS > 80).
Magaji et al. [32] Poor Indeterminate
Stoma (yes vs. no) Patients with a stoma had significantly higher
symptom scores related to blood and mucus in
stool, flatulence, fecal incontinence, sore skin,
and embarrassment, compared with patients
without a stoma.
Performance status
(Karnofsky score ≤ 80 vs. > 80)
No significant differences were found between
patients with lower (KPS ≤ 80) and higher
(KPS > 80) performance status.
Montazeri et al. [33] Poor Indeterminate
Stoma (yes vs. no) Patients with a stoma had significantly higher
symptoms scores related to urinary frequency,
blood and mucus in stool, stool frequency,
urinary incontinence, abdominal pain, buttock
pain, bloating, flatulence, fecal incontinence,
sore skin, embarrassment, and dyspareunia,
compared with patients without a stoma.
Nowak et al. [34] Poor Indeterminate
Sex (males vs. females) No significant differences were found between
men and women.
Stoma (yes vs. no) Patients with a stoma had a significant lower
(median) functioning scores related to body
image, lower symptom scores related to
flatulence, and higher symptom scores related
to abdominal pain, compared with patients
without stoma.
Sanna et al. [35] Poor Indeterminate
Stoma (yes vs. no) Patients with a stoma had significant higher
functioning scores related to body image,
lower functioning scores related to sexual
interest (women), and higher symptom
scores related to urinary incontinence,
abdominal pain, buttock pain, impotence
(men), and dyspareunia (women), compared
with patients without stoma.
Age (< 65 years vs. ≥ 65 years) Older patients (≥ 65 years) had significant
lower functioning scores related to sexual
interest (men) and sexual interest (women),
higher symptom scores related to urinary
frequency, dry mouth, taste, embarrassment
(stoma patients), and stoma care problems
(stoma patients), and lower symptom scores
related to bloating and dyspareunia (women),
compared with younger patients (< 65 years).
Treatment intent
(Curative vs. palliative)
Patients treated with curative intent
had significant higher functioning
scores related to sexual interest
(men), lower functioning scores
related to anxiety, higher symptom
scores related to buttock pain,
flatulence (patients without stoma),
stool frequency (patients without
stoma), fecal incontinence (patients
with stoma), and lower symptom
scores related to hair loss and taste,
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Table 4 (continued)
Reference Comparison groups Outcome a Quality Rating
compared with patients treated
with palliative intent.
Shen et al. [36] Fair Insufficient
Treatment
(active treatment vs.
follow-up)
Patients with active treatment had a
significant higher symptom score
related to blood and mucus in stool,
compared with patients during
follow-up.
ECOG status score
(ECOG= 0 vs.
ECOG = 1–3)
Patients with a high performance status
(ECOG= 0) had a significant higher
symptom score related to urinary
frequency, compared with patients
with a lower performance status
(ECOG= 1–3).
Bristol Stool Scale (BSS)
(BSS = 0–4 vs. BSS = 5–6)
No significant differences were found
between patients with diarrhea
(BSS = 5–6) and without diarrhea
(BSS = 0–4).
Stoma (yes vs. no) Patients with a stoma had significant
higher symptom scores related to
fecal incontinence and sore skin,
compared to patient without a stoma.
Surgery (minimally
invasive vs. laparotomy)
Patients with a minimally invasive
surgery had a significant lower
symptom score related to buttock
pain, compared to patients with a
laparotomy.
Adjuvant therapy
(yes vs. no)
Patient with adjuvant therapy had a
significant higher symptom score
related to hair loss, compared to
patients without adjuvant therapy.
Stiggelbout et al. [37] Poor Indeterminate
Age (≤ 65 years vs.
≥ 66 years)
Older patients (≥ 66 years) had
significantly lower functioning
scores related to sexual interest
(men) and sexual interest
(women), and higher symptom
scores related to urinary frequency,
urinary incontinence and dry mouth,
compared with younger patients
(≤ 65 years).
Stoma (yes vs. no) Patients with a stoma had significantly
higher functioning scores related to
body image and weight, and higher
symptom scores related to urinary
incontinence, buttock pain and
impotence (men), compared with
patients without a stoma.
Treatment intent
(curative vs. palliative)
Patients treated with curative intent had
significantly higher symptom scores
related to blood and mucus in stool
and buttock pain, and lower symptom
scores related to hair loss and taste,
compared with patients treated with
palliative intent.
Whistance et al. [11] Poor Indeterminate
Stoma (yes vs. no) Patients with a stoma had significantly
higher functioning scores related to
body image, and higher symptom
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correlations (< 0.70) were reported in two remaining studies for
the UF subscale, and in one of the two studies for multiple single
items [30, 35]. Based on these findings, evidence on reliability
was rated as “insufficient,” because ofmultiple unacceptable ICC
values across studies. Quality of evidence was graded as “mod-
erate,” because only studies of fair and poor quality were found.
Measurement error
None of the studies reported onmeasurement error. However,
standard error of measurement (SEM) and smallest detectable
change (SDC) could be calculated for four studies reporting
on test–retest reliability [30, 35–37], using the ICCs and stan-
dard deviations of the subscales and single items
(Supplementary Table 2). Methodological quality of two stud-
ies was rated as “fair” [30, 35], because of the moderate sam-
ple size. Two studies were rated as “poor” [36, 37], because of
the small sample size. SDC scores ranged between 9.41 and
54.21, representing 9–54% of the scale of the QLQ-CR29 (0–
100). However, because the minimal important change (MIC)
was not reported, measurement error could not be interpreted.
Based on these findings, the evidence on measurement error
was rated as “indeterminate.”
Construct validity (hypothesis testing)
Known-group comparison
Ten studies performed a known-group comparison; a compar-
ison of subgroups based on sociodemographic and/or clinical
variables where differences in QLQ-CR29 scores should be
expected (Table 4). Methodological quality of eight studies
was rated as “poor” [11, 30–35, 37], because they did not
formulate a priori hypotheses about expected differences be-
tween groups. Two studies were rated as “fair” [28, 36], be-
cause it was not described how missing items were handled.
The studies of fair quality showed multiple differences in sub-
scales and items between known-groups, but confirmed less
than 75% of their hypotheses, leading to an “insufficient”
rating. The studies of poor quality found multiple differences
between groups (e.g., difference in taste for stoma vs. no sto-
ma group), but careful interpretation is warranted, because no
hypotheses were formulated, therefore leading to an “indeter-
minate” rating.
Convergent validity
Eight studies investigated convergent validity (Table 5).
Methodological quality of seven studies were rated as “poor”
[28, 30–33, 35, 37], because a priori hypotheses about expect-
ed correlations were not reported, and/or information on the
measurement properties of the comparator instrument was not
provided. One study was rated as “good” [29]. In this study,
the comparator instrument was the low anterior resection syn-
drome (LARS) score (measuring bowel dysfunction after
sphincter-preserving surgery among rectal cancer patients
[29, 39]). All five of the a priori formulated hypotheses were
confirmed, leading to a “sufficient” rating. In the studies of
poor quality, the comparator instrument was the QLQ-C30.
The QLQ-C30 is the core questionnaire of the EORTC QLQ
questionnaires [6]. Most studies showed that functional sub-
scales of the QLQ-CR29 were positively correlated with
Table 4 (continued)
Reference Comparison groups Outcome a Quality Rating
scores related to urinary frequency,
urinary incontinence, fecal
incontinence, sore skin and
embarrassment, compared with
patients without stoma.
Performance status
(Karnofsky score
< 80 vs. > 80)
Patients with a lower performance
status (KPS < 80) had significantly
higher symptom scores related to
stool frequency, abdominal pain,
bloating, dry mouth and flatulence,
compared with patients with a higher
performance status (KPS > 80).
Treatment intent
(curative vs.
palliative)
Patients treated with curative intent
had significantly higher symptom
scores related to dyspareunia
(women), and lower symptom
scores related to hair loss, compared
with patients treated with
palliative intent.
a Higher functional scores = better functioning, higher symptom scores = more problems
2404 Support Care Cancer (2019) 27:2395–2412
Table 5 Convergent validity of the QLQ-CR29
Reference Comparison instrument Correlations Quality Rating
Arraras et al. [28] QLQ-C30 C30 social functioning and CR29 body image, 0.57
C30 emotional functioning and CR29 body image, 0.51
C30 pain and CR39 abdominal pain, 0.51
C30 constipation and CR29 buttock pain, 0.52
C30 diarrhea and CR29 fecal incontinence, 0.51
Poor Indeterminate
Hou et al. [29] LARS score Total LARS score and QLQ-CR29 flatulence, 0.49
Total LARS score and QLQ-CR29 fecal incontinence, 0.55
Total LARS score and QLQ-CR29 sore skin, 0.39
Total LARS score and QLQ-CR29 stool frequency, 0.57
Total LARS score and QLQ-CR29 embarrassment, 0.48
Good Sufficient
Ihn et al. [30] QLQ-C30 Correlations between subscales of the QLQ-CR29 and QLQ-C30
were low (r < 0.40) in most cases, whereas several areas with
more related content showed higher correlations (r ≥ 0.40).
Most functional subscales of the QLQ-CR29 were positively
correlated with functional scales of the QLQ-C30, and negatively
correlated with symptom scales of the QLQ-C30. In addition,
most symptom scales were positively correlated with symptom
scales of the QLQ-C30, and negatively correlated with
functional scales.
Poor Indeterminate
Lin et al. [31] QLQ-C30 QLQ-C29 abdominal pain showed high correlations with
QLQ-C30 pain (r = 0.65), and QLQ-C30 fatigue (r = 0.41).
QLQ-CR29 anxiety showed high negative correlations with
QLQ-C30 role functioning (r = −0.43), QLQ-C30 emotional
functioning (r = − 0.55) and QLQ-C30 social functioning
(r = − 0.41), and a positive correlation with QLQ-C30
financial problems (r = 0.45). QLQ-CR29 showed high
correlations with QLQ-C30 blood and mucus in stool and
QLQ-C30 quality of life (r = − 0.41), pain (r = 0.45), and
diarrhea (r = 0.53). QLQ-CR29 body image, buttock pain,
hair loss, bloating, fecal incontinence, sore skin and
dyspareunia had correlation coefficients with QLQ-C30
nausea/vomiting that were higher than 0.4, and the
correlations between the stool frequency and diarrhea as
well as taste and appetite loss were also greater than 0.4.
Poor Indeterminate
Magaji et al. [32] QLQ-C30 Numerous significant correlations were observed between
subscales of the QLQ-C30 and QLQ-CR29. These correlations
were mostly weak (r ≤ 0.50). The strongest positive correlation
was between QLQ-C30 financial difficulty and QLQ-CR29
stoma care problems (r = 0.71), and the strongest negative
correlation was between QLQ-C30 emotional functioning
and QLQ-CR29 stoma care problems (r = − 0.71).
Poor Indeterminate
Montazeri et al. [33] QLQ-C30 In general, functional scales of the QLQ-CR29 were positively
correlated with the QLQ-C30 functional scales, and negatively
correlated with QLQ-C30 symptom scales, and the QLQ-CR29
symptom scales were positively correlated with the QLQ-C30
symptom scales, and negatively correlated with the QLQ-C30
functional scales. These correlations were mostly weak (r < 0.40).
Poor Indeterminate
Sanna et al. [35] QLQ-C30 Most correlations between QLQ-C30 and QLQ-CR29 subscales
were low (r < 0.40). The highest correlation was found between
QLQ-C30 emotional functioning and QLQ-CR29 body image
(r = 0.66). In general, the functional scales of the QLQ-CR29 were
positively correlated with the QLQ-C30 functional scales, and
negatively correlated with QLQ-C30 symptom scales, and the
QLQ-CR29 symptom scales were positively correlated with the
QLQ-C30 symptom scales, and negatively correlated with the
QLQ-C30 functional scales.
Poor Indeterminate
Stiggelbout et al. [37] QLQ-C30 Correlations between the subscales of the QLQ-CR29 and QLQ-C30
were below 0.40, except for the subscales QLQ-CR29 body
image and QLQ-C30 social functioning (r = 0.48), which
correlated moderately.
Poor Indeterminate
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functional scales of the QLQ-C30, and negatively correlated
with symptom scales of the QLQ-C30, and that most QLQ-
CR29 symptom scales were positively correlated with symp-
tom scales of the QLQ-C30, and negatively correlated with
functional scales of the QLQ-C30. As there were no a priori
hypotheses reported in most of these studies, results are diffi-
cult to interpret. While some scales make theoretical sense to
be correlated (e.g., functional scales: QLQ-C30 emotional
functioning and QLQ-CR29 anxiety), many scales are likely
unrelated (e.g., symptom scales: QLQ-C30 insomnia and
QLQ-CR29 hair loss). Due to the diversity of subscale con-
structs, the results were rated as “indeterminate” in these
studies.
Divergent validity
Two studies investigated divergent validity. Methodological
quality was rated as “poor” [11, 28], because a priori hypoth-
eses about expected correlations were not reported, and infor-
mation on the measurement properties of the comparator in-
strument was not provided. In both studies, the comparator
instrument was the QLQ-C30 [6]. One study reported corre-
lations between the two instruments of < 0.02 for most sub-
scales [28], and the other reported correlations of < 0.40 in all
subscales [11]. As was the case for convergent validity, due to
the diversity of subscale constructs it is difficult to determine
which subscales should be unrelated and which should be
related. As such, we rated these results as “indeterminate.”
Based on these findings, construct validity (hypothesis
testing) was rated overall as “inconsistent.” Most studies did
not report a priori hypotheses, and therefore could not be
interpreted. Three remaining studies provided an “insuffi-
cient” rating for known-group comparison [28, 36], and a
“sufficient” rating for convergent validity [29], leading to the
overall “inconsistent” rating. Quality of evidence was graded
as “moderate,” because mostly studies of fair and poor quality
were found.
Responsiveness
Two studies investigated responsiveness. Methodological
quality of these studies was rated as “poor” [11, 33], because
a priori hypotheses about changes in scores were not reported.
Sensitivity to measure change in HRQOL was tested in pa-
tients before and within 2 years after stoma closure, and in
patients receiving palliative chemotherapy and 3 months later
[11], and before and after neoadjuvant or palliative chemo-
therapy [33]. A statistically significant reduction was found
of the symptoms scores on weight [11], and BMS, SF, urinary
frequency, urinary incontinence, dysuria, buttock pain,
bloating, and taste [33] after chemotherapy. Other scores were
unchanged, as was the case after stoma closure. Based on
these findings and the fact that no correlations with changes
in instruments measuring related constructs were reported, the
evidence on responsiveness was rated “indeterminate.”
Summarized ratings of the results and the overall quality of
evidence of all measurement properties are shown in Table 6.
Discussion
The QLQ-CR29 is a well-known and commonly used PROM,
which was published in 2007, following revision of the QLQ-
CR38. Both instruments cover a wide range of symptoms
among CRC patients. This review shows that current evidence
on the measurement properties of the QLQ-CR29 is limited.
For each of the 11 studies included in the review, methodo-
logical quality per measurement property was rated most often
as “fair” or “poor.” Evidence of internal consistencywas rated
as “sufficient,” reliability as “insufficient,” construct validity
(hypotheses testing) as “inconsistent,” and structural validity,
measurement error, and responsiveness as “indeterminate.”
Most studies performed indirect measurements of structur-
al validity. With PCA, one of the original subscales could not
be confirmed but was changed into a new subscale [37]. We
Table 6 Summary of results and
quality of the evidence of the
measurement properties of the
QLQ-C29
Measurement property Results Quality of evidence
Content validity NA NA
Structural validity Indeterminate –
Internal consistency Sufficient Low
Reliability Insufficient Moderate
Measurement error Indeterminate –
Construct validity (hypothesis testing) Inconsistent Moderate
Known-group comparison Sufficient
Convergent validity Insufficient
Divergent validity Indeterminate
Cross-cultural validity NA NA
Responsiveness Indeterminate –
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recommend future studies to perform CFA, to confirm either
the original or newly found factor structure. Subsequently,
internal consistency should be assessed on those subscales
that are confirmed to be unidimensional.
Reliability appears to be a concern for the QLQ-CR29.
Further investigation is necessary, using ICC to control for
systematic error variance. These data can also be used to as-
sessmeasurement error, by calculating SDC. The SDC should
be compared with the MIC, in order to determine whether the
smallest change in scores that can be detected is smaller than
the change that is minimally important for patients, and is not
due, with 95% certainty, to measurement error.
Criterion validity cannot be assessed for the QLQ-CR29,
since there is no “gold standard” for measuring HRQOL.
Therefore, it is important to assess construct validity by for-
mulating hypotheses, a priori, for (1) known-group differ-
ences and (2) assessing convergent and divergent validity with
other PROMs, including direction and magnitude.
Hypotheses that can be confirmed contribute to construct
validity. The aim of the studies included in this review was
primarily to determine whether there was overlap between the
QLQ-C30 and QLQ-CR29, and not to specifically test for
convergent/divergent validity. Therefore, construct validity
of the QLQ-CR29 needs to be investigated further with a
priori formulated hypotheses. The same applies to
responsiveness, which needs to be investigated in groups that
are known to change, with a priori formulated hypotheses.
While none of the studies reported on tests of cross-cultural
validity (i.e., measurement invariance), the original validation
study was performed in an international sample [11].
Additional, formal tests of measurement invariance would
be useful.
The strength of the current review is that we closely follow-
ed the COSMIN guidelines during all steps of this review. A
limitation is that we used a precise instead of a sensitive search
filter for measurement properties in the literature search,
which has a lower sensitivity (93 vs. 97%) [22]. Therefore,
we cannot rule out that some additional validation studies of
the QLQ-CR29 might have been missed.
This review indicates that additional, better quality research
is needed on the measurement properties of the QLQ-CR29.
Future validation studies should focus on assessing structural
validity and subsequently internal consistency on subscales
that are unidimensional, reliability and thereby measurement
error, construct validity (hypothesis testing), and
responsiveness with a priori hypotheses, and cross-cultural
validity. It is thereby recommended to use the COSMIN
methodology.
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Appendix. Search terms
Embase.com
(‘Perceived Stress Scale’/de OR ‘Insomnia Severity Index’/de
OR ‘International Index of Erectile Function’/de OR ((cancer
NEAR/3 worr* NEAR/3 scale*) OR (patient NEAR/3
specifieke NEAR/3 klacht*) OR (insomni* NEAR/3 sever*
NEAR/3 index*) OR (6-item NEAR/6 female NEAR/3 sexu-
al* NEAR/3 function*) OR (5-item NEAR/6 erectile NEAR/3
function*) OR (sexual* NEAR/3 health NEAR/3 inventor*
NEAR/3 men) OR (body NEAR/3 image NEAR/3 scal*) OR
((EORTC OR ‘European Organization for Research and
Treatment of Cancer’) NEAR/6 (QLQ OR ‘Quality of Life’)
NEAR/6 (PATSAT32 OR BR23 OR BR-23 OR CR-29 OR
CR29 OR H&N25 OR HN25 OR HN-25)) OR (Caron
NEAR/3 screening NEAR/3 questionnaire*) OR (Jong
NEAR/3 Gierveld NEAR/3 loneliness) OR (7-item NEAR/3
dyadis NEAR/3 adjustment*) OR (vragenlijst NEAR/3
gezinskenmerken) OR (job NEAR/3 content* NEAR/3 ques-
tionnaire*) OR (vragenlijst NEAR/3 beleving NEAR/3
beoordeling NEAR/3 arbeid) OR (Alcohol NEAR/3 five-shot)
OR (perceived NEAR/3 stress NEAR/3 scale*) OR (functional
NEAR/3 assessment NEAR/3 cancer NEAR/3 therap*
NEAR/3 endocrine) OR (breast NEAR/3 impact NEAR/3
treatment NEAR/3 scale*) OR (breast NEAR/3 reconstruction
NEAR/3 satisfaction NEAR/3 questionnair*) OR (breast
NEAR/3 cancer NEAR/3 patients NEAR/3 needs NEAR/3
questionnaire*) OR (stoma NEAR/3 quality NEAR/3 life
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NEAR/3 questionnaire*) OR (shoulder* NEAR/3 disabilit*
NEAR/3 questionnaire*) OR ((‘CWS’ OR ‘SPK’ OR ‘FSFI-
6’ OR ‘IIEF-5’ OR ‘CARON’ OR ‘JGLS’ OR ‘DAS-7’ OR
‘VGK-SF’ OR ‘JCQ’ OR ‘VBBA’ OR ‘A5S’ OR ‘FACT-ES’
OR ‘BITS’ OR ‘BRECON-31’ OR ‘BR-CNPQ’ OR ‘SDQ’
OR ‘stoma-QoL’) NEAR/3 (assess* OR score* OR scale*
OR questionnaire* OR inventor* OR measure*))):ab,ti) AND
(neoplasm/exp OR (neoplas* OR cancer* OR oncolog* OR
tumor* OR tumour OR carcino*):ab,ti) AND (‘validation
study’/de OR ‘reproducibility’/de OR ‘psychometry’/de OR
‘observer variation’/de OR ‘discriminant analysis’/de OR ‘cor-
relation coefficient’/de OR reliability/de OR ‘sensitivity and
specificity’/de OR validity/exp OR ‘sensitivity analysis’/de
OR ‘internal consistency’/de OR ‘confidence interval’/de OR
(psychometr* OR reproducib* OR clinimetr* OR clinometr*
OR observer-varia* OR reliab* OR valid* OR coefficient OR
interna*-consisten* OR (cronbach* NEAR/3 (alpha OR al-
phas)) OR (item* NEXT/1 (correlation* OR selection* OR
reduction*)) OR agreement OR precision OR imprecision
OR precise-value* OR test*-retest* OR (test NEAR/3 retest)
OR (reliab* NEAR/3 (test OR retest)) OR stability OR
interrater OR inter-rater OR intrarater OR intra-rater OR
intertester OR inter-tester OR intratester OR intra-tester OR
interobserver OR inter-observer OR intraobserver OR intra-
observer OR intertechnician OR inter-technician OR
intratechnician OR intra-technician OR interexaminer OR
inter-examiner OR intraexaminer OR intra-examiner OR
interassay OR inter-assay OR intraassay OR intra-assay OR
interindividual OR inter-individual OR intraindividual OR
intra-individual OR interparticipant OR inter-participant OR
intraparticipant OR intra-participant OR kappa OR kappa-s
OR kappas OR (coefficient* NEAR/3 variation*) OR
repeatab* OR ((replicab* OR repeat*) NEAR/3 (measure OR
measures OR findings OR result OR results OR test OR tests))
OR generaliza* OR generalisa* OR concordance OR
(intraclass NEAR/3 correlation*) OR discriminative OR
‘known group’ OR (factor* NEAR/3 (analys* OR structure*))
OR dimensionality OR subscale* OR (multitrait NEAR/3 scal-
ing) OR item-discriminant* OR (interscale NEAR/3 correlat*)
OR ((error OR errors) NEAR/3 (measure* OR correlat* OR
evaluat* OR accuracy OR accurate OR precision OR mean))
OR ((individual OR interval OR rate OR analy*) NEAR/3
variabilit*) OR (uncertaint* NEAR/3 (measure*)) OR (error
NEAR/3 measure*) OR sensitiv* OR responsive* OR (limit
NEAR/3 detection) OR (minimal* NEAR/3 detectab*) OR
interpretab* OR (small* NEAR/3 (real OR detectable)
NEAR/3 (change OR difference)) OR (meaningful* NEAR/3
change*) OR (minimal* NEAR/3 (important OR detectab*OR
real) NEAR/3 (change*OR difference)) OR ((ceilingOR floor)
NEXT/1 effect*) OR ‘Item responsemodel’OR IRTORRasch
OR ‘Differential item functioning’ OR DIF OR ‘computer
adaptive testing’ OR ‘item bank’ OR ‘cross-cultural equiva-
lence’ OR (confidence* NEAR/3 interval*)):ab,ti)
Medline Ovid
(((cancer ADJ3 worr* ADJ3 scale*) OR (patient ADJ3
specifieke ADJ3 klacht*) OR (insomni* ADJ3 sever* ADJ3
index*) OR (6-item ADJ6 female ADJ3 sexual* ADJ3 func-
tion*) OR (5-item ADJ6 erectile ADJ3 function*) OR (sexu-
al* ADJ3 health ADJ3 inventor* ADJ3men) OR (body ADJ3
image ADJ3 scal*) OR ((EORTC OR “European
Organization for Research and Treatment of Cancer”) ADJ6
(QLQ OR “Quality of Life”) ADJ6 (PATSAT32 OR BR23
OR BR-23 OR CR-29 OR CR29 OR H&N25 OR HN25
OR HN-25)) OR (Caron ADJ3 screening ADJ3 question-
naire*) OR (Jong ADJ3 Gierveld ADJ3 loneliness) OR (7-
item ADJ3 dyadis ADJ3 adjustment*) OR (vragenlijst ADJ3
gezinskenmerken) OR (job ADJ3 content* ADJ3 question-
naire*) OR (vragenlijst ADJ3 beleving ADJ3 beoordeling
ADJ3 arbeid) OR (Alcohol ADJ3 five-shot) OR (perceived
ADJ3 stress ADJ3 scale*) OR (functional ADJ3 assessment
ADJ3 cancer ADJ3 therap* ADJ3 endocrine) OR (breast
ADJ3 impact ADJ3 treatment ADJ3 scale*) OR (breast
ADJ3 reconstruction ADJ3 satisfaction ADJ3 questionnair*)
OR (breast ADJ3 cancer ADJ3 patients ADJ3 needs ADJ3
questionnaire*) OR (stoma ADJ3 quality ADJ3 life ADJ3
questionnaire*) OR (shoulder* ADJ3 disabilit* ADJ3 ques-
tionnaire*) OR ((“CWS” OR “SPK” OR “FSFI-6” OR “IIEF-
5” OR “CARON” OR “JGLS” OR “DAS-7” OR “VGK-SF”
OR “JCQ” OR “VBBA” OR “A5S” OR “FACT-ES” OR
“BITS” OR “BRECON-31” OR “BR-CNPQ” OR “SDQ”
OR “stoma-QoL”) ADJ3 (assess* OR score* OR scale* OR
questionnaire* OR inventor* OR measure*))).ab,ti.) AND
(neoplasm/ OR (neoplas* OR cancer* OR oncolog* OR tu-
mor* OR tumour OR carcino*).ab,ti.) AND (exp “Validation
Studies”/ OR exp “reproducibility of results”/ OR exp “psy-
chometrics”/ OR exp “observer variation”/ OR exp “discrim-
inant analysis”/ OR exp “Sensitivity and Specificity”/ OR
“Confidence Intervals”/ OR (psychometr* OR reproducib*
OR clinimetr* OR clinometr* OR observer-varia* OR reliab*
OR valid* OR coefficient OR interna*-consisten* OR
(cronbach* ADJ3 (alpha OR alphas)) OR (item* ADJ (corre-
lation* OR selection* OR reduction*)) OR agreement OR
precision OR imprecision OR precise-value* OR test*-retest*
OR (test ADJ3 retest) OR (reliab* ADJ3 (test OR retest)) OR
stability OR interrater OR inter-rater OR intrarater OR intra-
rater OR intertester OR inter-tester OR intratester OR intra-
tester OR interobserver OR inter-observer OR intraobserver
OR intra-observer OR intertechnician OR inter-technician OR
intratechnician OR intra-technician OR interexaminer OR
inter-examiner OR intraexaminer OR intra-examiner OR
interassay OR inter-assay OR intraassay OR intra-assay OR
interindividual OR inter-individual OR intraindividual OR
intra-individual OR interparticipant OR inter-participant OR
intraparticipant OR intra-participant OR kappa OR kappa-s
OR kappas OR (coefficient* ADJ3 variation*) OR repeatab*
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OR ((replicab* OR repeat*) ADJ3 (measure ORmeasures OR
findings OR result OR results OR test OR tests)) OR
generaliza* OR generalisa* OR concordance OR (intraclass
ADJ3 correlation*) OR discriminative OR “known group”
OR (factor* ADJ3 (analys* OR structure*)) OR dimensional-
ity OR subscale* OR (multitrait ADJ3 scaling) OR item-dis-
criminant* OR (interscale ADJ3 correlat*) OR ((error OR
errors) ADJ3 (measure* OR correlat* OR evaluat* OR accu-
racy OR accurate OR precision OR mean)) OR ((individual
OR interval OR rate OR analy*) ADJ3 variabilit*) OR
(uncertaint* ADJ3 (measure*)) OR (error ADJ3 measure*)
OR sensitiv* OR responsive* OR (limit ADJ3 detection)
OR (minimal* ADJ3 detectab*) OR interpretab* OR (small*
ADJ3 (real OR detectable) ADJ3 (change OR difference)) OR
(meaningful* ADJ3 change*) OR (minimal* ADJ3 (impor-
tant OR detectab* OR real) ADJ3 (change* OR difference))
OR ((ceiling OR floor) ADJ effect*) OR “Item response mod-
el”OR IRTORRasch OR “Differential item functioning”OR
DIF OR “computer adaptive testing” OR “item bank” OR
“cross-cultural equivalence” OR (confidence* ADJ3
interval*)).ab,ti.)
PsycINFO Ovid
(((cancer ADJ3 worr* ADJ3 scale*) OR (patient ADJ3
specifieke ADJ3 klacht*) OR (insomni* ADJ3 sever* ADJ3
index*) OR (6-item ADJ6 female ADJ3 sexual* ADJ3 func-
tion*) OR (5-item ADJ6 erectile ADJ3 function*) OR (sexu-
al* ADJ3 health ADJ3 inventor* ADJ3men) OR (body ADJ3
image ADJ3 scal*) OR ((EORTC OR “European
Organization for Research and Treatment of Cancer”) ADJ6
(QLQ OR “Quality of Life”) ADJ6 (PATSAT32 OR BR23
OR BR-23 OR CR-29 OR CR29 OR H&N25 OR HN25
OR HN-25)) OR (Caron ADJ3 screening ADJ3 question-
naire*) OR (Jong ADJ3 Gierveld ADJ3 loneliness) OR (7-
item ADJ3 dyadis ADJ3 adjustment*) OR (vragenlijst ADJ3
gezinskenmerken) OR (job ADJ3 content* ADJ3 question-
naire*) OR (vragenlijst ADJ3 beleving ADJ3 beoordeling
ADJ3 arbeid) OR (Alcohol ADJ3 five-shot) OR (perceived
ADJ3 stress ADJ3 scale*) OR (functional ADJ3 assessment
ADJ3 cancer ADJ3 therap* ADJ3 endocrine) OR (breast
ADJ3 impact ADJ3 treatment ADJ3 scale*) OR (breast
ADJ3 reconstruction ADJ3 satisfaction ADJ3 questionnair*)
OR (breast ADJ3 cancer ADJ3 patients ADJ3 needs ADJ3
questionnaire*) OR (stoma ADJ3 quality ADJ3 life ADJ3
questionnaire*) OR (shoulder* ADJ3 disabilit* ADJ3 ques-
tionnaire*) OR ((“CWS” OR “SPK” OR “FSFI-6” OR “IIEF-
5” OR “CARON” OR “JGLS” OR “DAS-7” OR “VGK-SF”
OR “JCQ” OR “VBBA” OR “A5S” OR “FACT-ES” OR
“BITS” OR “BRECON-31” OR “BR-CNPQ” OR “SDQ”
OR “stoma-QoL”) ADJ3 (assess* OR score* OR scale* OR
questionnaire* OR inventor* OR measure*))).ab,ti.) AND
(neoplasm/ OR (neoplas* OR cancer* OR oncolog* OR
tumor* OR tumour OR carcino*).ab,ti.) AND (exp “Test
Validity”/ OR exp “Test Reliability”/ OR exp “psychomet-
rics”/ OR exp “Interrater Reliability”/ OR exp OR
(psychometr* OR reproducib* OR clinimetr* OR clinometr*
OR observer-varia* OR reliab* OR valid* OR coefficient OR
interna*-consisten* OR (cronbach* ADJ3 (alpha OR alphas))
OR (item* ADJ (correlation* OR selection* OR reduction*))
OR agreement OR precision OR imprecision OR precise-val-
ue* OR test*-retest* OR (test ADJ3 retest) OR (reliab* ADJ3
(test OR retest)) OR stability OR interrater OR inter-rater OR
intrarater OR intra-rater OR intertester OR inter-tester OR
intratester OR intra-tester OR interobserver OR inter-
observer OR intraobserver OR intra-observer OR
intertechnician OR inter-technician OR intratechnician OR
intra-technician OR interexaminer OR inter-examiner OR
intraexaminer OR intra-examiner OR interassay OR inter-
assay OR intraassay OR intra-assay OR interindividual OR
inter-individual OR intraindividual OR intra-individual OR
interparticipant OR inter-participant OR intraparticipant OR
intra-participant OR kappa OR kappa-s OR kappas OR (coef-
ficient* ADJ3 variation*) OR repeatab* OR ((replicab* OR
repeat*) ADJ3 (measure OR measures OR findings OR result
OR results OR test OR tests)) OR generaliza* OR generalisa*
OR concordance OR (intraclass ADJ3 correlation*) OR dis-
criminative OR “known group” OR (factor* ADJ3 (analys*
OR structure*)) OR dimensionality OR subscale* OR
(multitrait ADJ3 scaling) OR item-discriminant* OR
(interscale ADJ3 correlat*) OR ((error OR errors) ADJ3 (mea-
sure* OR correlat* OR evaluat* OR accuracy OR accurate
OR precision ORmean)) OR ((individual OR interval OR rate
OR analy*) ADJ3 variabilit*) OR (uncertaint* ADJ3 (mea-
sure*)) OR (error ADJ3 measure*) OR sensitiv* OR respon-
sive* OR (limit ADJ3 detection) OR (minimal* ADJ3
detectab*) OR interpretab* OR (small* ADJ3 (real OR de-
tectable) ADJ3 (change OR difference)) OR (meaningful*
ADJ3 change*) OR (minimal* ADJ3 (important OR
detectab* OR real) ADJ3 (change* OR difference)) OR ((ceil-
ing OR floor) ADJ effect*) OR “Item response model” OR
IRT OR Rasch OR “Differential item functioning” OR DIF
OR “computer adaptive testing” OR “item bank” OR “cross-
cu l t u r a l equ i va l ence” OR (con f i d ence* ADJ3
interval*)).ab,ti.)
Web of science
TS = ((((cancer NEAR/3 worr* NEAR/3 scale*) OR (patient
NEAR/3 specifieke NEAR/3 klacht*) OR (insomni* NEAR/3
sever* NEAR/3 index*) OR (6-item NEAR/6 female
NEAR/3 sexual* NEAR/3 function*) OR (5-item NEAR/6
erectile NEAR/3 function*) OR (sexual* NEAR/3 health
NEAR/3 inventor* NEAR/3 men) OR (body NEAR/3 image
NEAR/3 scal*) OR ((EORTC OR “European Organization
for Research and Treatment of Cancer”) NEAR/6 (QLQ OR
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“Quality of Life”) NEAR/6 (PATSAT32 OR BR23 ORBR-23
OR CR-29 OR CR29 OR H&N25 OR HN25 OR HN-25))
OR (Caron NEAR/3 screening NEAR/3 questionnaire*) OR
(Jong NEAR/3 Gierveld NEAR/3 loneliness) OR (7-item
NEAR/3 dyadis NEAR/3 adjustment*) OR (vragenlijst
NEAR/3 gezinskenmerken) OR (job NEAR/3 content*
NEAR/3 questionnaire*) OR (vragenlijst NEAR/3 beleving
NEAR/3 beoordeling NEAR/3 arbeid) OR (Alcohol
NEAR/3 five-shot) OR (perceived NEAR/3 stress NEAR/3
scale*) OR (functional NEAR/3 assessment NEAR/3 cancer
NEAR/3 therap* NEAR/3 endocrine) OR (breast NEAR/3
impact NEAR/3 treatment NEAR/3 scale*) OR (breast
NEAR/3 reconstruction NEAR/3 satisfaction NEAR/3
questionnair*) OR (breast NEAR/3 cancer NEAR/3 patients
NEAR/3 needs NEAR/3 questionnaire*) OR (stoma NEAR/3
quality NEAR/3 life NEAR/3 questionnaire*) OR (shoulder*
NEAR/3 disabilit* NEAR/3 questionnaire*) OR ((“CWS”
OR “SPK” OR “FSFI-6” OR “IIEF-5” OR “CARON” OR
“JGLS” OR “DAS-7” OR “VGK-SF” OR “JCQ” OR
“VBBA” OR “A5S” OR “FACT-ES” OR “BITS” OR
“BRECON-31” OR “BR-CNPQ” OR “SDQ” OR “stoma-
QoL”) NEAR/3 (assess* OR score* OR scale* OR question-
naire* OR inventor* OR measure*)))) AND (neoplasm/exp
OR (neoplas* OR cancer* OR oncolog* OR tumor* OR tu-
mour OR carcino*)) AND ((psychometr* OR reproducib*
OR clinimetr* OR clinometr* OR observer-varia* OR reliab*
OR valid* OR coefficient OR interna*-consisten* OR
(cronbach* NEAR/3 (alpha OR alphas)) OR (item* NEAR/1
(correlation* OR selection* OR reduction*)) OR agreement
OR precision OR imprecision OR precise-value* OR test*-
retest* OR (test NEAR/3 retest) OR (reliab*NEAR/3 (test OR
retest)) OR stability OR interrater OR inter-rater OR intrarater
OR intra-rater OR intertester OR inter-tester OR intratester
OR intra-tester OR interobserver OR inter-observer OR
intraobserver OR intra-observer OR intertechnician OR
inter-technician OR intratechnician OR intra-technician OR
interexaminer OR inter-examiner OR intraexaminer OR
intra-examiner OR interassay OR inter-assay OR intraassay
OR intra-assay OR interindividual OR inter-individual OR
intraindividual OR intra-individual OR interparticipant OR
inter-participant OR intraparticipant OR intra-participant OR
kappa OR kappa-s OR kappas OR (coefficient* NEAR/3 var-
iation*) OR repeatab* OR ((replicab* OR repeat*) NEAR/3
(measure OR measures OR findings OR result OR results OR
test OR tests)) OR generaliza* OR generalisa* OR concor-
dance OR (intraclass NEAR/3 correlation*) OR discrimina-
tive OR “known group” OR (factor* NEAR/3 (analys* OR
structure*)) OR dimensionality OR subscale* OR (multitrait
NEAR/3 scaling) OR item-discriminant* OR (interscale
NEAR/3 correlat*) OR ((error OR errors) NEAR/3 (measure*
OR correlat* OR evaluat* OR accuracy OR accurate OR pre-
cision OR mean)) OR ((individual OR interval OR rate OR
analy*) NEAR/3 variabilit*) OR (uncertaint* NEAR/3
(measure*)) OR (error NEAR/3 measure*) OR sensitiv* OR
responsive* OR (limit NEAR/3 detection) OR (minimal*
NEAR/3 detectab*) OR interpretab* OR (small* NEAR/3
(real OR detectable) NEAR/3 (change OR difference)) OR
(meaningful* NEAR/3 change*) OR (minimal* NEAR/3 (im-
portant OR detectab* OR real) NEAR/3 (change* OR differ-
ence)) OR ((ceiling OR floor) NEAR/1 effect*) OR “Item
response model” OR IRT OR Rasch OR “Differential item
functioning” OR DIF OR “computer adaptive testing” OR
“item bank” OR “cross-cultural equivalence” OR (confi-
dence* NEAR/3 interval*))))
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